Prevision Policy Clips | CMS Medicare Drug Spend Dashboards Released May 15

CMS Medicare/Medicaid Dashboard Updated With Focus On Price Increases To Federal Programs

AstraZeneca Using Patient Input To Design Better, Less-Expensive Clinical Trials; Fasenra and Anifrolumab Are Case Studies

Senate Health Committee Plans Drug Pricing Hearing Following President’s Plan; 340B Oversight Continues With Third Hearing To Come

Prevision Policy Clips | HHS Drug Pricing Plan, Request For Information Appear In Federal Register

Achondroplasia Clinical Trial Review By FDA Panel Reaches Consensus on Randomized Trials, Annual Growth Velocity Endpoint

Drug Pricing Plan First Steps: Policy Changes Start “This Week” – But With Small Steps

Tougher Talk On Drug Prices From HHS Secretary Azar: Beware The Bully Pulpit

Prevision Policy Clips | Pediatric Cancer Study Plan Workshop Focus of Oncologic Drugs Advisory Committee Meeting

Drug Pricing’s Made-For-TV Moment: Key Takeaways From The Rose Garden Event

Part B Reforms In Drug Pricing Plan May Have Biggest Impact: Reviving “CAP” Among “Immediate” Actions; “Site Neutrality,” Part D Merger Are Longer-Term Ideas

Akcea Triglyceride-Lowering Drug Volanesorsen Squeaks By Advisory Committee; FDA In A Bind Given Thrombocytopenia Risk

Prevision Policy Clips | The Reality Show President Makes Drug Pricing “Must See TV”

HHS’ Azar Delivers Drug Pricing Preview At Senate Appropriations Hearing: “All Players Will Be Impacted”

Tissue Agnostic Cancer Approvals Complicate Orphan Drug Designations; FDA Plans Guidance Soon – With Eye Toward Non-Cancer Implications

Prevision Policy Clips | OTC Monograph Reform/User Fee Bill Moves To House Floor

Wholesalers Offer Opioid Mea Culpas: House Hearing With CEOs Stays Mostly Friendly – And May Offer Lessons For Manufacturers; Focus Shifts Back To DEA

Insulin Price Increases Spotlighted By Senate Aging Committee Ahead of Trump Drug Pricing Plan

Prevision Policy Clips | Novartis Says Contract With Trump Attorney Ended In February

Akcea’s Volanesorsen: “Rapid and Unpredictable” Platelet Reduction Risk May Be Too Difficult To Overcome For FDA’s E&M Advisory Committee

Prevision Policy Clips | HHS Secretary Azar Will Testify on Senate Appropriations

FDA’s Gottlieb Unfazed By Drug Review Staff Turnover; Says Hiring Challenges With Aging Workforce Can Be Addressed Via “Cures”

FDA New Drug Review Modernization Will Include Rethinking Of Safety Office Role, Woodcock Says

Prevision Policy Clips | New Acting Office of Orphan Products Development Director Will Be Ilan Irony

Mallinckrodt’s Stannsoporfin: FDA Panel Votes Down Jaundice Drug On Possible Neurodevelopmental Risks, Lack of Clinical Efficacy